AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05247242 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Get Active with Virtual Reality (VR)
Description: Participants will utilize the Oculus Quest 2 virtual reality headset, which is a head-mounted display system where users can interact with a virtual environment in a gaming setting. The Oculus Quest 2 incorporates social features where participants can interact with other users. This VR intervention will include periods of gameplay where participants can play games in either competitive or cooperative settings. This intervention will last six weeks.
Study NCT06787339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 650mg/m2, bid, p.o for 1 year
Study NCT06784635 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In person
Description: Participant dyads will meet in person for a mock clinical interview, seated at a desk opposite their counterpart. They will be in an office setting. There will be a sham white noise and lamp device placed on the desk.
Study NCT06784635 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online interaction
Description: Participant dyads will meet online in a mock clinical interview, via an encrypted video call, seated at a desk. They will be in an office setting. There will be a sham white noise and lamp device placed on the desk.
Study NCT06783634 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Group 2 (dexamethasone group) single intra venous high dose of dexamethasone 1mg/kg with maximum dose of 100 mg.
Study NCT06783634 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Group 1 (Control group) will receive normal saline as a placebo.
Study NCT06784518 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical scores and functional MRI
Description: Motor evoked potentials between Day 3-Day 7 of the stroke, for a equal distribution of patients into three prognostic groups according to the PREP2 algorithm (good, limited and poor). Longitudinal follow-up with clinical scores and functional MRI at Day 7-Day 10, Day 30, Month 3 and Month 6 of stroke.
Study NCT06788002 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-dose radiotherapy combine with chemoimmunotherapy
Description: Radiation: 1.4Gy for 5 days to the liver metastasis before chemoimmunotherapy. Chemoimmunotherapy: gemcitabine(1000mg per square meter on days 1,8) , cisplatin (80mg per square meter on day 1), penpulimab (200mg, day1)
Study NCT06782984 — intervention group
Intervention type: OTHER
Intervention: Organoid-based drug sensitivity test
Description: The intervention in this study involves utilizing glioblastoma organoids (GBOs) to perform an organoid-based drug sensitivity test (DST) and retrospectively comparing the results with clinical outcomes. Notably, no interventions will be applied to participants based on GBO-DST results; the study is limited to retrospective analysis.~The GBO-DST is conducted by performing a drug response assay with temozolomide to determine the half-maximal inhibitory concentration (IC50), which serves to classify GBOs as TMZ-sensitive or TMZ-resistant. This classification is further validated through GBO cell survival analysis.
Study NCT06011954 — intervention group
Intervention type: DRUG
Intervention: Enfortumab Vedotin
Description: Intravenous
Study NCT05561738 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nicotinamide Riboside Chloride
Description: The intervention consists of 6 months to 1 year of daily oral therapy with Nicotinamide Riboside Chloride (Niagen) in addition to standard therapy.
Study NCT05561738 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The intervention consists of 6 months to 1 year of daily oral therapy with placebo (Maltodextran capsules of similar size, shape and color as Niagen) in addition to standard therapy.
Study NCT05561738 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of Care
Study NCT04077749 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Femdophilus probiotic
Description: Lactobacillus rhamnosus (GR-1®) and reuteri (RC-14®) species, which is offered as an over the counter probiotic capsule sold under the brand name of Femdophilus dissolved in 50 mL normal saline at room temperature.
Study NCT04077749 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 50 mL normal saline at room temperature
Study NCT06414772 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use of MARTI application in addition with a classical consultation/support
Description: Participants will use MARTI in order to establish the medical history during their waiting time.
Study NCT04985578 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: The therapist will located the TrP that refers the most pain and will apply manual compression until the participant will reported pain. After that, dry needling technique will be performed on the TrP for 60 seconds.
Study NCT04985578 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham dry needling
Description: The therapist will located the TrP that refers the most pain and will apply manual compression until the participant will reported pain. After that, dry needling technique will be performed on the TrP for 60 seconds with a sham needle without tip.
Study NCT06785285 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: To compare the effects of fentanyl and dexmedetomidine when used as adjuvants to intrathecal bupivacaine in elective cesarean section, assessing their impact on the onset and duration of spinal anesthesia, quality of analgesia, hemodynamic stability, incidence of side effects, and neonatal outcomes
Study NCT06786702 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic TAPP (Trans Abdominal Pre-Peritoneal) hernia repair: Round Ligament Preservation
Description: Group 1 (Round Ligament Preservation): Patients will undergo laparoscopic TAPP surgery with the round ligament preserved. The preservation will be achieved using a longitudinal incision technique in the peritoneum.
Study NCT06786702 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic TAPP (Trans Abdominal Pre-Peritoneal) hernia repair: Round Ligament Cutting
Description: Group 2 (Round Ligament Cutting): Patients will undergo laparoscopic TAPP surgery with the round ligament cut close to the peritoneum using an energy device.
Study NCT06785688 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Protective gear irradiated by infrared rays
Description: irradiated by infrared rays back brace
Study NCT06788093 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ED Clinical Decision Support (CDS-ED)
Description: The ED-CDS intervention is designed as a discrete decision support aid to influence initial antibiotic decision-making in the ED. This intervention will feature a clinician-facing LRTI dashboard for end-users that assimilates relevant clinical data (e.g., vital signs, select diagnostic tests, links to reference information) and offers tailored suggestions for antibiotic initiation, related diagnostic testing, and in those receiving antibiotics, preferred options and alternatives for antibiotic choice, route, dose, and duration.
Study NCT06788093 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transitions Clinical Decision Support (CDS-Tr)
Description: The CDS-Tr intervention is designed as a longitudinal decision support aid to influence initial and ongoing (i.e., continuation, discontinuation, escalation, or de-escalation) antibiotic decision-making in the hospital setting. This intervention will also feature the LRTI dashboard along with additional tailored suggestions and recommendations for antibiotic decision-making upon hospital admission, and for those receiving antibiotics, at the time of discharge. Additionally, CDS-Tr will be active at the time of any service transition (i.e., hospital to intensive care or vice versa) and at pre-specified time points (e.g., approximately 48 hours and 120 hours following ED triage for encounters remaining in the hospital).
Study NCT06786793 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computer-aided detection (CADe)
Description: Endo-Aid CADe system is an AI-assisted computer-aided lesion detection application on ENDO-AID hardware. It uses a complex algorithm created via a neural network developed and taught by Olympus. With this new app, the sophisticated machine learning system can alert the endoscopist in real-time when a suspicious lesion appears on the screen. The image from the vision processor is transferred to the CADe device. The computer application recognizes the shape of the polyps and marks their place on the monitor screen.
Study NCT06786273 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: Small RNA sequencing
Description: The blood and endometrial tissue samples collected from the study groups will undergo small RNA sequencing to investigate the microRNA expression profiles associated with that phase.
Study NCT06784908 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yale Pain Stress Task (YPST)
Description: Individuals in the experimental cohort will be scheduled for 2 experimental sessions 1-3 days apart. The YPST stress experiment includes a stress and no-stress session (order randomly assigned, counter-balanced across subjects), and involves multiple (up to 3) unpredictable number of consecutive 3-minute trials of ice-bath (stress) or warm-bath (no stress) forearm immersion (stress) with subjective, physiologic endocrine and immune assessments repeated at specified time points.
Study NCT06783920 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: music
Description: music will be played during the copper IUD insertion
Study NCT06783920 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: no music
Description: IUD insertion will be done as usual without music
Study NCT06782581 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contribution to Caregivers Well-Being
Description: Contribute to caregiver's well-being via household tasks.
Study NCT06782581 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: factually describe either (1) immediate environment, (2) the weather, or (3) organization of closet
Study NCT06785129 — intervention group
Intervention type: DEVICE
Intervention: Thermal stimuli
Description: The Thermal Sensory Analyzer (TSA-II or PATHWAY platform - Medoc, Ramat Yishai, Israel) will be used to safely deliver heat and cold stimuli. These devices can deliver relatively complex stimuli via computer control. All targeted stimulus temperatures will be less than 50°C, and participants will be free to remove their arm or leg at any time from the thermode. Noxious cold stimuli will also be delivered with a plastic water container or a water bath (FISHER, USA). Participants will be free to pull out of the water bath at any time
Study NCT06785129 — intervention group
Intervention type: DEVICE
Intervention: Pressure stimuli
Description: Pressure stimuli will be applied by using a handheld algometer (Wagner Instruments) or the Pressure Algometer (Medoc, Ramat Yishai, Israel). These devices have a round probe that allows quantifying the amount of pressure that is being applied. The Pressure Algometer allows a real-time visual feedback to control and monitor applied pressure rates. Pressure will be applied to the lower leg, volar forearm, or trapezius.
Study NCT06785129 — intervention group
Intervention type: BEHAVIORAL
Intervention: Pain ratings
Description: Pain intensity and pain unpleasantness ratings will be assessed.
Study NCT06785129 — intervention group
Intervention type: BEHAVIORAL
Intervention: Conditioned pain modulation (CPM) response
Description: The CPM paradigm assesses endogenous inhibitory pain modulation efficiency. CPM testing includes the application of a test stimulus without conditioning (control run, pressure pain thresholds) and a subsequent application of the same test stimulus together with a conditioning stimulus (conditioning run, a 60 second of foot immersion in cold water). The CPM response is the difference in the pressure pain thresholds between the control and the conditioning runs.
Study NCT06785129 — intervention group
Intervention type: BIOLOGICAL
Intervention: Hormonal assessment
Description: Blood samples (approximetly 2 tablespoons) and/or saliva and/or urine will be collected for analyses of sex hormone levels (e.g., prolactin, testosterone, estradiol).
Study NCT06784440 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: Evaluation of circulating donor free DNA in the recipient's blood (Dd-cfDNA: donor-derived cell free DNA)
Description: From the blood samples taken, 2 mL of plasma separated from blood will be stored in EDTA frozen at -80°C. This material will later be processed by NGS run using of CareDX kits. The result will be provided by dedicated software as percentage of donor DNA in relation to recipient DNA.
Study NCT06779201 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting
Description: One-week fasting without limit of water drink (Participants can feel free to drink water )
Study NCT06787976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir (DTG)
Description: Dolutegravir + Tenofovir Disoproxil Fumarate / Emtricitabine
Study NCT06787976 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darunavir/Cobicistat (FDC)
Description: Darunavir Cobicistat + TDF/FTC
Study NCT06784791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amivantamab Intravenous
Description: Stage 1: Pre-operative amivantamab monotherapy Stage 2: Pre-operative amivantamab treatment plus chemotherapy (carboplatin/pemetrexed)
Study NCT06784791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin/Pemetrexed
Description: Stage 2: Pre-operative amivantamab plus chemotherapy (carboplatin/pemetrexed)
Study NCT06786182 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PFM Educational Program
Description: A structured telematic educational program covering PFM anatomy, function, and proper activation techniques. Content includes videos, visual guides, and exercises aimed at promoting PFM co-contraction and awareness.
Study NCT06785857 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mHealth Supportive Care Program
Description: On the basis of monthly home visits in the control group, a weekly mHealth supportive care intervention program was added through the medium of Xiamen iHealth, with one supportive care item every two weeks for 12 weeks, for a total of 12 online interventions, as well as the provision of online consulting and booking services for caregivers at any time.
Study NCT06785857 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Offline supportive care
Description: This was done routinely in accordance with the requirements of public health services for chronic diseases in the community elderly. In addition, health education on diabetes mellitus and dementia was provided to the caregivers during their monthly home visits.~① the content of diabetes health education: the researcher gave the caregivers education and training on the care of diabetes patients: the main points of care in diet, sleep, exercise, etc.~② The content of dementia health education: the researcher gave the caregivers education and training related to the care of dementia patients: instructing the caregivers in the basic life care skills of patients' diet, sleep, exercise, etc.
Study NCT06783816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chimeric antigen receptor gene modified T cells
Description: The rate of intravenous infusion of CAR T cells was 10 mL to 20 mL/min, and the infusion was performed using a blood transfusion apparatus with a filter screen. Use saline rinsing tube prior to infusion; Rinse the infusion bag with 10 mL\~30 mL normal saline.
Study NCT06786260 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interventional Diet
Description: Low salt, limited caffeine, high potassium, low phosphate, and limited protein and carbohydrate intake along with adequate water intake diet
Study NCT06786130 — intervention group
Intervention type: OTHER
Intervention: observational study
Description: This is an observational study in which participants complete PRO questionnaires via a web platform. No medical intervention or medication is involved.
Study NCT06787430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicorandil
Description: In the nicorandil group, intracoronary nicorandil 3mg dissolved in 3ml saline was given within 30 seconds at two time points, one was when the guidewire or ballon passed the lesion and the blood flow was regained, and another was the time before the stent was implanted.
Study NCT06787430 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline (NaCl 0,9 %) (placebo)
Description: In the control group, 3ml saline was given intracoronary through the guiding catheter within 30 seconds at the same time points in nicorandil group.
Study NCT06782724 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Psilocybin therapy
Description: Psilocybin therapy consisting of three preparation, two dosing, and three integration sessions. All sessions will take place in a controlled, safety environment and supported by two study therapists
Study NCT06782724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin therapy
Description: Psilocybin therapy consisting of three preparation, two dosing, and three integration sessions. All sessions will take place in a controlled, safety environment and supported by two study therapists
Study NCT06785519 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19/BCMA Lupus Nephritis Targeted CAR T-cells injection
Description: Each subject receive CD19/BCMA Lupus Nephritis Targeted CAR T-cells by intravenous infusion
Study NCT06782841 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GMA-TULIP Laryngeal Mask
Description: After the anesthesia induction, use the GMA-TULIP laryngeal mask as the airway ventilation device.
Study NCT06782841 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: i-gel Laryngeal Mask
Description: After the anesthesia induction, use the i-gel laryngeal mask as an airway ventilation device.
Study NCT06321120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: variability-based lenvatinib regimen
Description: Dosages and administration times were tailored within individual predefined ranges to accommodate personalized therapeutic regimens. As per protocol, the daily dose was limited to match or remain below the patients' pre-enrollment dosage level. In the initial 4 weeks of the follow-up, participants followed a fixed standard regimen with the app serving as a reminder, allowing for an adaptation period. Subsequently, the algorithm-driven treatment plan was implemented for an additional 10 weeks.
Study NCT05600153 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: implant exchange operation
Description: To perform implant exchange via axillary incision.
Study NCT05600153 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: implant exchange operation
Description: To perform implant exchange via axillary incision.
Study NCT06782841 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BlockBuster Laryngeal Mask
Description: After the anesthesia induction is over, use the BlockBuster laryngeal mask as the airway ventilation device.
Study NCT06786442 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EFFACLAR DUO+M CREAM
Description: twice a day: morning and evening. Subjects should be able to self-apply the product on all assessment areas (face, upper chest, and back)
Study NCT06784570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levosemindan
Description: In common practice the loading dose is omitted as it is associated with hypotension.9 Usual dose range: 0.05 to 0.2 microg/kg/min. Dose based on actual body weight up to a maximum of 120 kg.5 Commence infusion at 0.05 microg/kg/min. If the initial rate is tolerated, consider increasing the maintenance rate to 0.1 microg/kg/min after 60 minutes. If the patient remains haemodynamically stable, further increase the dose to 0.2 microg/kg/min for the remainder of the infusion.
Study NCT06784570 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adrenaline,noreadrenaline,dopamine and doputamine
Description: adrenaline:\*4 9 %$ 0 \*\*\*\*8\*4\* 9 : ,- 4 - \*4 9 \* C % F\*4 9 9 9 noreadrenaline:# \*4 9 C % 9 F 9 9 \*4\* Q\*4 9 9 dopamine:9 \* C % 9 F 9 9 ) \* 9 9 dobutamine:9 \* C % F 9 9 9 \* 9 9
Study NCT06785571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine hydrochloride injection
Description: a loading dose of Nalbuphine hydrochloride injection administered in 30 ±10 seconds, followed by a maintenance dose of 2.0mg/h (a recommended maintenance dose range of 1.0\~5.0mg/h)
Study NCT06785571 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone hydrochloride injection
Description: A maintenance dose of 0.5mg/h (a recommended maintenance dose range of 0.5\~3.0mg/h)
Study NCT06784193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OP-3136
Description: OP-3136
Study NCT05771454 — intervention group
Intervention type: PROCEDURE
Intervention: Histopathological confirmation
Description: After mastectomy, each specimen will be assessed histopathologically for the presence or absence of invasive focus of breast cancer.
Study NCT03843320 — intervention group
Intervention type: DEVICE
Intervention: SAPIEN 3
Description: Transcatheter aortic valve replacement
Study NCT03843320 — intervention group
Intervention type: DEVICE
Intervention: SAPIEN XT
Description: Transcatheter aortic valve replacement
Study NCT03843320 — intervention group
Intervention type: DEVICE
Intervention: INSPIRIS RESILIA
Description: Surgical aortic valve replacement
Study NCT03843320 — intervention group
Intervention type: DEVICE
Intervention: EDWARDS INTUITY
Description: Surgical aortic valve replacement
Study NCT03843320 — intervention group
Intervention type: DEVICE
Intervention: Carpentier-Edwards PERIMOUNT Magna-Ease
Description: Surgical aortic valve replacement